H. Lundbeck A/S (LON: 0ND5)
London
· Delayed Price · Currency is GBP · Price in DKK | Market Cap | 4.38B |
| Revenue (ttm) | 2.39B |
| Net Income (ttm) | 299.84M |
| Shares Out | n/a |
| EPS (ttm) | 0.30 |
| PE Ratio | 14.59 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Mar 21, 2024 |
| Volume | 17,169 |
| Average Volume | 37,653 |
| Open | 39.92 |
| Previous Close | 40.12 |
| Day's Range | 39.80 - 40.40 |
| 52-Week Range | 3.51 - 5.48 |
| Beta | n/a |
| RSI | 43.16 |
| Earnings Date | Feb 5, 2025 |
About H. Lundbeck
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat M... [Read more]
Financial Performance
In 2023, H. Lundbeck's revenue was 19.91 billion, an increase of 9.13% compared to the previous year's 18.25 billion. Earnings were 2.29 billion, an increase of 19.52%.
Financial numbers in DKK Financial StatementsNews
Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade)
Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with successful clinical trials.